Programmed cell death -1 protein/ligand inhibitor - Adlai Nortye/Institute of Materia Medica

Drug Profile

Programmed cell death -1 protein/ligand inhibitor - Adlai Nortye/Institute of Materia Medica

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Materia Medica
  • Developer Adlai Nortye; Institute of Materia Medica
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CD274 antigen inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Metabolic disorders

Most Recent Events

  • 03 Nov 2017 Adlai Nortye expects to file IND applications to US FDA and China FDA in 2019
  • 31 Oct 2017 Adlai Nortye enters into an agreement with Institute of Materia Medica for worldwide development and commercialistion of a PD-1/L1 inhibitor
  • 31 Oct 2017 Early research in Cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top